Начало・Списък с акции・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Отворен

СекторЗдравеопазване

39.07 4.27

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

37.29

Максимум

39.07

Ключови измерители
By Trading Economics
Приходи	2.6M -79M
Продажби	-60K 15K
EPS	-1.18
Марж на печалбата	-524,566.667
Служители	198
EBITDA	2.7M -78M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+51.02% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	226M 2.8B
Предишно отваряне	34.8
Предишно затваряне	39.07

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Celldex Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:53 ч. UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31.07.2026 г., 19:36 ч. UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30.07.2026 г., 18:51 ч. UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29.07.2026 г., 20:03 ч. UTC

Macro Event

News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28.07.2026 г., 19:36 ч. UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27.07.2026 г., 19:31 ч. UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22.07.2026 г., 20:01 ч. UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21.07.2026 г., 23:01 ч. UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Сравнение с други в отрасъла

Ценова промяна

Celldex Therapeutics Inc Прогноза

Ценова цел

By TipRanks

51.02% нагоре

12-месечна прогноза

Среден 56.92 USD 51.02%

Висок 100 USD

Нисък 34 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Celldex Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Celldex Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.